Showing results (71-80 of 212) with videos related to

Sort By:
Pageof 22
Bioconjugate Chemistry|May 18, 2006
Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugatesScott C Jeffrey, Jamie B Andreyka, Starr X Bernhardt, et al.
ACS Medicinal Chemistry Letters|July 16, 2025
Auristatin S: An Auristatin Payload with Improved Tolerability and Modified Bystander ActivityPhilip N Moquist, Nicole M-L Eng-Duncan, Tim D Bovee, et al.
Bioconjugate Chemistry|January 19, 2006
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicitySvetlana O Doronina, Brian A Mendelsohn, Tim D Bovee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugatesChe-Leung Law, Charles G Cerveny, Kristine A Gordon, et al.
Bioconjugate Chemistry|December 5, 2008
Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2Shannon J Sirk, Tove Olafsen, Bhaswati Barat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugateKevin J Hamblett, Peter D Senter, Dana F Chace, et al.
Bioconjugate Chemistry|March 16, 2006
Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)Ralph F Alderson, Brian E Toki, Martin Roberge, et al.
Molecular Cancer Therapeutics|December 8, 2020
Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor ModelsPhilip N Moquist, Tim D Bovee, Andrew B Waight, et al.
Nature Biotechnology|May 29, 2019
A coiled-coil masking domain for selective activation of therapeutic antibodiesVivian H Trang, Xinqun Zhang, Roma C Yumul, et al.
Cancer Research|November 18, 2008
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivoDowdy Jackson, John Gooya, Shenlan Mao, et al.
Pageof 22